Economic evaluation alongside n-of-1 trials: getting closer to the margin.
The n-of-1 trial is a particularly flexible form of randomized controlled trial that involves a single patient receiving multiple episodes of alternative therapies. Although n-of-1 trials are only applicable in certain treatment areas, the collection of economic data within such trials may provide unique advantages. This paper illustrates the issues around the use of economic n-of-1 trials with a hypothetical example, and discusses their potential for the estimation of individualized cost-effectiveness.
Karnon
J
J
Health Economics Research Group, Brunel University, Uxbridge, UK. hesrjdk@brunel.ac.uk
Qizilbash
N
N
D000082:Acetaminophen / Q000191:economics / Q000627:therapeutic use; D018712:Analgesics, Non-Narcotic / Q000191:economics / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000191:economics / Q000627:therapeutic use; D002908:Chronic Disease / Q000191:economics; D003362:Cost-Benefit Analysis / Q000706:statistics & numerical data*; D017050:Episode of Care; D006801:Humans; D010003:Osteoarthritis / Q000188:drug therapy / Q000191:economics; D019057:Quality-Adjusted Life Years; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D018401:Sample Size
D018712:Analgesics, Non-Narcotic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000082:Acetaminophen